71 related articles for article (PubMed ID: 22338543)
21. Resistance profiles and adherence at primary virological failure in three different highly active antiretroviral therapy regimens: analysis of failure rates in a randomized study.
Røge BT; Barfod TS; Kirk O; Katzenstein TL; Obel N; Nielsen H; Pedersen C; Mathiesen LR; Lundgren JD; Gerstoft J
HIV Med; 2004 Sep; 5(5):344-51. PubMed ID: 15369509
[TBL] [Abstract][Full Text] [Related]
22. Long-term virological outcome and resistance mutations at virological rebound in HIV-infected adults on protease inhibitor-sparing highly active antiretroviral therapy.
de la Rosa R; Ruíz-Mateos E; Rubio A; Abad MA; Vallejo A; Rivero L; Genebat M; Sánchez-Quijano A; Lissen E; Leal M
J Antimicrob Chemother; 2004 Jan; 53(1):95-101. PubMed ID: 14657091
[TBL] [Abstract][Full Text] [Related]
23. [HIV-1 therapy in the Netherlands; virological and immunological response to antiretroviral therapy].
Jambroes M; Weverling GJ; Reiss P; Danner SA; Jurriaans S; ten Veen JH; van der Ende ME; Schutten M; Schneider MM; Schuurman R; Mulder JW; Kroes AC; Lange JM; de Wolf F;
Ned Tijdschr Geneeskd; 2001 Aug; 145(33):1591-7. PubMed ID: 11534377
[TBL] [Abstract][Full Text] [Related]
24. Determinants of virological failure after successful viral load suppression in first-line highly active antiretroviral therapy.
Geretti AM; Smith C; Haberl A; Garcia-Diaz A; Nebbia G; Johnson M; Phillips A; Staszewski S
Antivir Ther; 2008; 13(7):927-36. PubMed ID: 19043927
[TBL] [Abstract][Full Text] [Related]
25. A randomized, prospective study of phenotype susceptibility testing versus standard of care to manage antiretroviral therapy: CCTG 575.
Haubrich RH; Kemper CA; Hellmann NS; Keiser PH; Witt MD; Tilles JG; Forthal DN; Leedom J; Leibowitz M; McCutchan JA; Richman DD;
AIDS; 2005 Feb; 19(3):295-302. PubMed ID: 15718840
[TBL] [Abstract][Full Text] [Related]
26. Efficient suppression of minority drug-resistant HIV type 1 (HIV-1) variants present at primary HIV-1 infection by ritonavir-boosted protease inhibitor-containing antiretroviral therapy.
Metzner KJ; Rauch P; von Wyl V; Leemann C; Grube C; Kuster H; Böni J; Weber R; Günthard HF
J Infect Dis; 2010 Apr; 201(7):1063-71. PubMed ID: 20196655
[TBL] [Abstract][Full Text] [Related]
27. [Infections with human immunodeficiency viruses. Part II: Antiretroviral drugs, therapeutic options, and diagnostics].
Stock I
Med Monatsschr Pharm; 2011 Jul; 34(7):234-44; quiz 245-6. PubMed ID: 21809598
[TBL] [Abstract][Full Text] [Related]
28. Mutational patterns and correlated amino acid substitutions in the HIV-1 protease after virological failure to nelfinavir- and lopinavir/ritonavir-based treatments.
Garriga C; Pérez-Elías MJ; Delgado R; Ruiz L; Nájera R; Pumarola T; Alonso-Socas Mdel M; García-Bujalance S; Menéndez-Arias L;
J Med Virol; 2007 Nov; 79(11):1617-28. PubMed ID: 17854027
[TBL] [Abstract][Full Text] [Related]
29. HIV treatment options.
Smith D
AIDS Treat News; 1998 May; (No 294):4-5. PubMed ID: 11365404
[TBL] [Abstract][Full Text] [Related]
30. An introduction to nucleoside and nucleotide analogues.
Squires KE
Antivir Ther; 2001; 6 Suppl 3():1-14. PubMed ID: 11678469
[TBL] [Abstract][Full Text] [Related]
31. Intermittent viremia during first-line, protease inhibitors-containing therapy: significance and relationship with drug resistance.
Masquelier B; Pereira E; Peytavin G; Descamps D; Reynes J; Verdon R; Fleury H; Garraffo R; Chêne G; Raffi F; Brun-Vézinet F;
J Clin Virol; 2005 May; 33(1):75-8. PubMed ID: 15797369
[TBL] [Abstract][Full Text] [Related]
32. Options for a second-line antiretroviral regimen for HIV type 1-infected patients whose initial regimen of a fixed-dose combination of stavudine, lamivudine, and nevirapine fails.
Sungkanuparph S; Manosuthi W; Kiertiburanakul S; Piyavong B; Chumpathat N; Chantratita W
Clin Infect Dis; 2007 Feb; 44(3):447-52. PubMed ID: 17205457
[TBL] [Abstract][Full Text] [Related]
33. Absence of resistance mutations in antiretroviral-naive patients treated with ritonavir-boosted saquinavir.
Ananworanich J; Hirschel B; Sirivichayakul S; Ubolyam S; Jupimai T; Prasithsirikul W; Chetchotisakd P; Kiertiburanakul S; Munsakul W; Raksakulkarn P; Tansuphasawadikul S; Schutz M; Snowden W; Ruxrungtham K;
Antivir Ther; 2006; 11(5):631-5. PubMed ID: 16964832
[TBL] [Abstract][Full Text] [Related]
34. Overview of boosted protease inhibitors in treatment-experienced HIV-infected patients.
Youle M
J Antimicrob Chemother; 2007 Dec; 60(6):1195-205. PubMed ID: 17890281
[TBL] [Abstract][Full Text] [Related]
35. Less drug regimens and PI/r-based strategies in HIV infection: focus on best practices using the HIV patient's journey methodology.
Marcotullio S; Ammassari A; Andreoni M; Antinori A; Bonora S; d'Arminio Monforte A; Di Perri G; Galli M; Gervasoni C; Iardino R; Ippolito G; Lo Caputo S; Nozza S; Perno CF; Rizzardini G; Lazzarin A
New Microbiol; 2014 Apr; 37(2):163-75. PubMed ID: 24858643
[TBL] [Abstract][Full Text] [Related]
36. [Usefulness of antiretroviral resistance tests in the clinical practice].
Soriano Vázquez V; de Mendoza C; Gallego Donoso O; Valer López-Fando L; González-Lahoz J
Rev Clin Esp; 2001 Sep; 201(9):508-12. PubMed ID: 11692405
[No Abstract] [Full Text] [Related]
37. Using HIV drugs to target human papilloma virus.
Hampson L; Oliver AW; Hampson IN
Expert Rev Anti Infect Ther; 2014 Sep; 12(9):1021-3. PubMed ID: 25096249
[TBL] [Abstract][Full Text] [Related]
38. New therapeutic options for HIV patients.
Hillery A
Pharm Sci Technol Today; 1999 Oct; 2(10):389-390. PubMed ID: 10498916
[No Abstract] [Full Text] [Related]
39. The antiretroviral agent saquinavir enhances hTERT expression and telomerase activity in human T leukaemia cells in vitro.
Adamo R; Comandini A; Aquino A; Bonmassar L; Guglielmi L; Bonmassar E; Franzese O
J Exp Clin Cancer Res; 2013 Jun; 32(1):38. PubMed ID: 23759068
[TBL] [Abstract][Full Text] [Related]
40. Identification of novel HIV 1--protease inhibitors: application of ligand and structure based pharmacophore mapping and virtual screening.
Yadav D; Paliwal S; Yadav R; Pal M; Pandey A
PLoS One; 2012; 7(11):e48942. PubMed ID: 23145032
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
